阿戈美拉汀与米氮平治疗抑郁症伴睡眠障碍的效果对比  

Effect comparison of agomelatine and mirtazapine in the treatment of depression with sleep disorders

作　　者：蔡业清 CAI Ye-qing(Psychiatry Department,Dongguan Mental Health Center(Dongguan Seventh People’s Hospital),Dongguan 523000,China)

机构地区：[1]东莞市精神卫生中心(东莞市第七人民医院)精神科,523000

出　　处：《中国现代药物应用》2021年第4期28-30,共3页Chinese Journal of Modern Drug Application

摘　　要：目的对比阿戈美拉汀与米氮平治疗抑郁症伴睡眠障碍的效果。方法88例抑郁症伴睡眠障碍患者,随机分为对照组及观察组,各44例。对照组使用米氮平治疗,观察组使用阿戈美拉汀治疗。比较两组患者的临床疗效,治疗前后的汉密尔顿抑郁量表(HAMD-17)、蒙哥马利抑郁评定量表(MADRS)、匹兹堡睡眠质量指数量表(PSQI)评分,治疗前后的睡眠结构指标[睡眠潜伏期、睡眠效率、觉醒时间、思睡期(S1)+浅睡期(S2)、中度睡眠期(S3)+深睡期(S4)、快速眼动期(REM)、实际睡眠时间]。结果观察组患者的治疗总有效率为86.36%,明显高于对照组的68.18%,差异具有统计学意义(P<0.05)。治疗后,观察组患者的HAMD-17评分(11.92±2.83)分、MADRS评分(11.53±2.47)分、PSQI评分(5.45±1.03)分均明显低于对照组的(14.37±3.15)、(19.74±3.59)、(8.97±1.34)分,差异均具有统计学意义(P<0.05)。治疗后,观察组患者的睡眠潜伏期、觉醒时间、S1+S2均短于对照组,睡眠效率高于对照组,S3+S4、REM、实际睡眠时间均长于对照组,差异均具有统计学意义(P<0.05)。结论阿戈美拉汀治疗抑郁症伴睡眠障碍的效果更佳,对抑郁症状及睡眠结构均有明显改善效果,有助于调整睡眠周期,提升睡眠质量。Objective To compare the effect of agomelatine and mirtazapine in the treatment of depression with sleep disorders.Methods A total of 88 cases of depression with sleep disorder were randomly divided into control group and observation group,with 44 cases in each group.The control group was treated with mirtazapine,and the observation group was treated with agomelatine.The clinical efficacy,17-item Hamilton Depression Rating Scale(HAMD-17),Montgomery-Asberg depression rating scale(MADRS),Pittsburgh sleep quality index(PSQI)scores before and after treatment,sleep structure indicators[sleep latency,sleep efficiency,wake-up time,sleepiness(S1)+light sleep(S2),moderate sleep(S3)+deep sleep(S4),rapid eye movement(REM),actual sleep time]before and after treatment were compared between the two groups.Results The total effective rate of treatment of the observation group was 86.36%,which was obviously higher than 68.18%of the control group,and the difference was statistically significant(P<0.05).After treatment,the HAMD-17 score(11.92±2.83)points,MADRS score(11.53±2.47)points and PSQI score(5.45±1.03)points of the observation group were obviously lower than(14.37±3.15),(19.74±3.59)and(8.97±1.34)points of the control group,and the difference was statistically significant(P<0.05).After treatment,the sleep latency,wake-up time and S1+S2 of the observation group were shorter than those of the control group,sleep efficiency was higher than that of the control group,and S3+S4,REM and actual sleep time was longer than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Agomelatine is more effective in treating depression with sleep disorders.It has a significant improvement effect on depression symptoms and sleep structure,and helps to adjust the sleep cycle,improve sleep structure and sleep quality.

关 键 词：抑郁症伴睡眠障碍 阿戈美拉汀 米氮平 效果 对比 

分 类 号：R749.4[医药卫生—神经病学与精神病学] R740[医药卫生—临床医学]